Molecular Pathology of Cancer

癌症的分子病理学

• 批准号: 8550329
• 负责人: Boris C. Bastian
• 金额: $ 11.46万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-12 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8550329
• 关键词: Malignant Neoplasms; molecular pathology

DESCRIPTION (provided by applicant): This application is for a new institutional Ruth L. Kirschstein National Research Service Award (NRSA) T32 training grant to support the research training of six postdoctoral fellows in the Molecular Pathology of Cancer at the University of California, San Francisco (UCSF). The objective of this Program is to equip the most promising young cancer researchers recruited to our institution with the skills necessary both to advance scientific knowledge into human malignancy and effectively translate laboratory-based oncology discoveries into the clinic. Recent advances in molecular oncology and cancer genomics have created an unprecedented opportunity to study malignancy in cancer patients and their tissues, and use this information to develop mechanism-based diagnostic and therapeutic strategies to revolutionize patient care. The underlying rationale for this Program is that the development of personalized cancer therapy must be driven by the molecular pathology of the tumor. To keep pace with accelerating discoveries in cancer biology and catalyze clinical translation, we need to increase the number of highly trained translational physicians and scientists with an appreciation of the pathologic as well as genetic aberrations of cancer. This is the first training grant on this theme at UCSF and one of the few nationwide that brings together investigators focused on fundamental research in cancer biology, the molecular diagnosis of cancer, and personalized targeted therapy for cancer patients. Administration and scientific direction of the Program will be through the UCSF Departments of Pathology and Laboratory Medicine, providing an ideal setting where cutting edge cell and molecular biology expertise can be leveraged against our large tumor banks and combined with the newest technologies in cancer diagnostics. The 34 outstanding faculty members in the program are a mix of basic cancer biologists and physician-scientists with diverse clinical and scientific training in oncologic diseases. T32 trainees will receive highly personalized, multidisciplinary training that includes the following five key elements: (1) An intense research experience in which each trainee is co-mentored by a basic investigator and a clinical/translational scientist; (2) Hands-on exposure to a broad range of cancer-relevant analyses, including mutation panel testing and whole genome sequencing, bioinformatic approaches in a research setting and CLIA-licensed clinical laboratories; (3) Formal coursework in cancer biology, cancer pathology, translational oncology, and clinical trial development; (4) Weekly seminar series given by distinguished cancer researchers from outside academic institutions and bio/pharmaceutical companies in the Bay area and beyond; (5) Ongoing performance evaluation and formal career development workshops. We provide evidence that UCSF has the vision, expertise, and infrastructure to train the next generation of leaders in translational cancer research.

描述(由申请者提供)：本申请是为了申请一项新的机构Ruth L.Kirschstein国家研究服务奖(NRSA)T32培训补助金，以支持加州大学旧金山分校(UCSF)癌症分子病理学的六名博士后研究员的研究培训。该计划的目标是使我们研究所招募的最有前途的年轻癌症研究人员具备必要的技能，既可以将科学知识转化为人类恶性肿瘤，也可以有效地将基于实验室的肿瘤学发现转化为临床。分子肿瘤学和癌症基因组学的最新进展为研究癌症患者及其组织的恶性肿瘤创造了前所未有的机会，并利用这些信息开发基于机制的诊断和治疗策略，以彻底改变患者护理。这项计划的基本原理是，个性化癌症治疗的发展必须由肿瘤的分子病理学驱动。为了跟上癌症生物学加速发现的步伐并促进临床翻译，我们需要增加训练有素的翻译医生和科学家的数量，他们了解癌症的病理和遗传异常。这是第一次培训 格兰特在加州大学旧金山分校就这一主题进行了研究，也是全国为数不多的将专注于癌症生物学基础研究、癌症分子诊断和癌症患者个性化靶向治疗的研究人员聚集在一起的机构之一。该计划的管理和科学指导将通过加州大学旧金山分校的病理学和实验室医学系进行，提供了一个理想的环境，可以利用尖端细胞和分子生物学专业知识对抗我们的大型肿瘤库，并将其与癌症诊断领域的最新技术相结合。该项目中的34名优秀教职员工是基础癌症生物学家和内科科学家的混合体，他们在肿瘤学疾病方面接受过不同的临床和科学培训。T32学员将接受高度个性化的多学科培训，包括以下五个关键要素：(1)密集的研究经验，每个学员由一名基础研究人员和一名临床/翻译科学家共同指导；(2)亲身接触广泛的癌症相关分析，包括突变小组测试和全基因组测序、研究环境中的生物信息学方法和CLIA许可的临床实验室；(3)癌症生物学、癌症病理学、翻译肿瘤学和临床试验开发方面的正式课程；(4)由来自湾区内外学术机构和生物/制药公司的杰出癌症研究人员举办的每周系列研讨会；(5)持续的绩效评估和正式的职业发展讲习班。我们提供的证据表明，加州大学旧金山分校拥有培养下一代转化型癌症研究领导者的远见、专业知识和基础设施。